Funding agency DST

Start date May 12, 2023

End Date None

Duration None

Disease category Rare disorder

Type of study Invitro assay

Type of data Quantitative data

Aims of objective • To develop a cost-effective process for the synthesis of Cladribine, used for the treatment of adult patients with highly active forms of relapsing-remitting multiple sclerosis (MS) and for treating Langerhans cell histiocytosis (LCH). • To develop a process for the synthesis of palovarotene used for the treatment of heterotopic ossification (HO) and fibrodysplasiaossificance progressive (FOP).

Keyword Risdiplam, Cladribine, Palvoarotone, Rare disorders, Orphan drugs, Relaing-Remitting multiple sclerosis, Langerhans cell histiocytosis, Heterotopic ossification, Fibrodysplasia ossificane progressive

Description None

Total Sanctioned budget None